Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 6/20 | 0.45 |
| ▸ | HPGD | P15428 | 4/20 | 0.45 |
| ▸ | SMN1; SMN2 | Q16637 | 4/20 | 0.45 |
| ▸ | CYP1A2 | P05177 | 2/20 | 0.45 |
| ▸ | CYP2D6 | P10635 | 2/20 | 0.45 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.45 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.45 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.45 |
| ▸ | POLB | P06746 | 1/20 | 0.41 |
| ▸ | CYP19A1 | P11511 | 1/20 | 0.38 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.37 |
| ▸ | GRIN1 | Q05586 | 2/20 | 0.35 |
| ▸ | GRIN2B | Q13224 | 2/20 | 0.35 |
| ▸ | RAB9A | P51151 | 2/20 | 0.35 |
| ▸ | MEN1 | O00255 | 2/20 | 0.35 |
| ▸ | MAPT | P10636 | 2/20 | 0.35 |
| ▸ | ATM | Q13315 | 1/20 | 0.34 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.34 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.33 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL11653378 | 0.82 | MAPT (0.43) | ALDH1A1HPGDSMN1; SMN2CYP1A2CYP2D6 | |
| SCHEMBL28862271 | 0.81 | HPGD (0.34) | ALDH1A1HPGDSMN1; SMN2CYP1A2CYP2D6 | |
| SCHEMBL10824393 | 0.79 | CYP1A2 (0.53) | ALDH1A1HPGDSMN1; SMN2CYP1A2CYP2D6 | |
| SCHEMBL20786543 | 0.79 | POLB (0.38) | ALDH1A1HPGDSMN1; SMN2CYP1A2CYP2D6 | |
| SCHEMBL10824397 | 0.79 | CYP1A2 (0.53) | ALDH1A1HPGDSMN1; SMN2CYP1A2CYP2D6 | |
| SCHEMBL14006400 | 0.79 | CYP1A2 (0.53) | ALDH1A1HPGDSMN1; SMN2CYP1A2CYP2D6 | |
| SCHEMBL17028404 | 0.79 | KMT2A (0.53) | ALDH1A1HPGDSMN1; SMN2CYP1A2CYP2D6 | |
| SCHEMBL11461816 | 0.75 | TSHR (0.38) | ALDH1A1HPGDSMN1; SMN2CYP1A2CYP2D6 | |
| SCHEMBL17385699 | 0.74 | ATM (0.44) | ALDH1A1HPGDSMN1; SMN2POLBKMT2A | |
| SCHEMBL16473435 | 0.70 | GRIN1 (0.39) | ALDH1A1HPGDSMN1; SMN2CYP1A2CYP2D6 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 492 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-114105796-A | Synthetic method of stable isotope deuterium-labeled isoleucine | 上海化工研究院有限公司 | 2022-03-01 | — | — | CN | claimed |
| US-20090023919-A1 | SYNTHESIS OF TEMOZOLOMIDE AND ANALOGS | SCHERING CORPORATION | 2009-01-22 | — | — | US | claimed |
| US-20060229456-A1 | Synthesis of Temozolomide and analogs | SCHERING CORPORATION | 2006-10-12 | — | — | US | claimed |
| US-7087751-B2 | Diazotizing 5-amino-1H-imidazole-4-carboxamide derivative having divalent protecting group on amide that is readily removable by hydrolysis or hydrogenolysis | SCHERING CORPORATION (US) | 2006-08-08 | — | — | US | claimed |
| US-20050131227-A1 | Synthesis of temozolomide and analogs | SCHERING CORPORATION | 2005-06-16 | — | — | US | claimed |
| EP-1353924-A1 | SYNTHESIS OF TEMOZOLOMIDE AND ANALOGS | Schering Corporation (US) | 2003-10-22 | — | — | EP | claimed |
| WO-2002057269-A1 | SYNTHESIS OF TEMOZOLOMIDE AND ANALOGS | SCHERING CORPORATION (US) | 2002-07-25 | — | — | WO | claimed |
| US-20020095036-A1 | Synthesis of temozolomide and analogs | SCHERING CORPORATION | 2002-07-18 | — | — | US | claimed |
| US-6336963-B1 | INK COMPOSITION COMPRISING INK VEHICLE COMPRISING FIRST NITRILE COMPOUND HAVING FIRST VISCOSITY AT MELT TEMPERATURE, VISCOSITY MODIFIER COMPRISING SECOND NITRILE COMPOUND HAVING LOWER VISCOSITY AT MELT TEMPERATURE, COLORANT | XEROX CORPORATION | 2002-01-08 | — | — | US | claimed |
| JP-58150552-A | — | — | None | — | — | JP | disclosed |
| JP-58150553-A | — | — | None | — | — | JP | disclosed |
| JP-57130972-A | — | — | None | — | — | JP | disclosed |
| JP-58000955-A | — | — | None | — | — | JP | disclosed |
| JP-58000954-A | — | — | None | — | — | JP | disclosed |
| JP-S58954-A | PREPARATION OF PROPYLAMINE DERIVATIVE | TORAY IND INC | 1983-01-06 | — | — | JP | disclosed |
| JP-S58953-A | PREPARATION OF BUTYRIC ACID DERIVATIVE | TORAY IND INC | 1983-01-06 | — | — | JP | disclosed |
| JP-S57130972-A | PREPARATION OF INDOLE DERIVATIVE | TORAY IND INC | 1982-08-13 | — | — | JP | disclosed |
| JP-S57123163-A | 2-DIPHENYLMETHYLENEAMINO-3-INDOLEPROPIONITRILE | TORAY IND INC | 1982-07-31 | — | — | JP | disclosed |
| EP-0047516-A1 | Propylamine derivative and process of manufacturing the same | TORAY INDUSTRIES, INC. (JP) | 1982-03-17 | — | — | EP | disclosed |
| EP-0037271-A1 | Indole derivatives and process for preparing the same | TORAY INDUSTRIES, INC. (JP) | 1981-10-07 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090023919-A1 | SYNTHESIS OF TEMOZOLOMIDE AND ANALOGS | MGMT, TYMS, MCL1 | ALDH1A1 1791/4885HPGD 1353/4885SMN1; SMN2 2787/4885 |
| US-20050131227-A1 | Synthesis of temozolomide and analogs | MGMT, TYMS, MCL1 | ALDH1A1 1791/4885HPGD 1353/4885SMN1; SMN2 2787/4885 |
| US-20060229456-A1 | Synthesis of Temozolomide and analogs | MGMT, TYMS, MCL1 | ALDH1A1 1791/4885HPGD 1353/4885SMN1; SMN2 2787/4885 |
| US-20020095036-A1 | Synthesis of temozolomide and analogs | MGMT, TYMS, MCL1 | ALDH1A1 1791/4885HPGD 1353/4885SMN1; SMN2 2787/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.